Search clinical trials for: DM1

Total 239 results

Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2)

Metastatic Breast Cancer

United States, Korea, Republic of, United Kingdom, Germany, Spain, Taiwan, Australia, Canada, Italy
Consorzio Oncotech
Roche Pharma AG

Recruiting

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Breast Cancer

Italy
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)

Breast Cancer

Belgium, Israel, Spain, Sweden, United States, Switzerland, Russian Federation, Czech Republic, France, Canada, Germany, Korea, Republic of, Australia, Hungary, Thailand, United Kingdom, Italy, Brazil, Slovakia, Poland, India, Norway
Hoffmann-La Roche

Terminated

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) (TRAXHER2)

Breast Cancer | Gastric Cancer

Italy, Argentina, Canada, France, Greece, Portugal, Slovakia, Brazil, Russian Federation, Spain, Germany, Serbia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Breast Cancer

China
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS); Imsmed Incorporated

Completed

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

Myotonic Dystrophy

United States
Medtronic Diabetes
Medtronic Poland Spółka z ograniczoną odpowiedzialnością

Completed

Orchestra Pregnancy Observational Study in Poland

Pregnancy | Type 1 Diabetes Mellitus

Poland
University of Virginia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Novo... and other collaborators

Completed

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes (DSS)

Type1 Diabetes Mellitus

United States
University of Virginia
DexCom, Inc.

Completed

Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform

Diabetes Mellitus, Type 1

United States
Daniel Chernavvsky, MD, CRC
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom...

Completed

Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp

Type 1 Diabetes Mellitus

United States
Suzhou Zanrong Pharma Limited

Recruiting

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Advanced Solid Tumors | HER2-positive Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast Cancer

United States
Boehringer Ingelheim

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

Breast Cancer

Korea, Republic of, United States, Australia, China, Ukraine, Spain, United Kingdom, Turkey, Mexico, Brazil, Belgium, Denmark, Germany, Greece, Portugal, Russian Federation, Taiwan, France, Kenya, Thailand, Romania, Italy, Czechia, Hu... and more
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Wilms Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Recurrent Synovial Sarcoma | Pleuropulmonary Blastoma

United States
The Methodist Hospital Research Institute
Novartis; Celgene Corporation

Completed

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel (TEAL)

Breast Cancer

United States
Otto Metzger, MD
Genentech, Inc.

Active, not recruiting

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)

Metastatic Breast Cancer

Korea, Republic of, United Kingdom, Australia, China, Croatia, Finland, France, Norway, Portugal, Slovenia, Canada, Italy, Spain, Colombia, Brazil, Poland, United States, Greece, Turkey, Russian Federation, Philippines
IRCCS San Raffaele

Not yet recruiting

AI-Predicted Disease Trajectories in Diabetes: A Retrospective Study (AI-TRYDIA)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Italy
Enliven Therapeutics

Recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)

HER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 Amplification

Spain, United States, Korea, Republic of, Taiwan, Italy, Australia, France
Genentech, Inc.
Hoffmann-La Roche

Recruiting

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Neoplasm Metastasis

Australia, Korea, Republic of, China, United States, Portugal, Brazil, Singapore, Spain, United Kingdom, Belgium, Austria, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Me... and more
University of Virginia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

Type 1 Diabetes Mellitus

United States
Oregon Health and Science University
Society of Family Planning

Completed

Regulation of Cervical Mucus Secretion

Contraception | Fertility

United States
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Terminated

Study of Antithymocyte Globulin for Treatment of New-onset T1DM (START)

New-onset Type 1 Diabetes Mellitus

United States
Dana-Farber Cancer Institute
Puma Biotechnology, Inc.; Translational Breast Cancer Research Consortium

Active, not recruiting

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Breast Cancer

United States
Jules Bordet Institute
Hoffmann-La Roche; Breast International Group; Institut Curie; International Drug...

Suspended

De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)

HER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast Cancer

Korea, Republic of, France, Israel, Belgium, Switzerland, Australia
Tianjin University of Traditional Chinese Medicine
National Basic Research Program, China

Unknown

Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting

Chemotherapy-induced Nausea and Vomiting

China
LMU Klinikum

Completed

Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders

Healthy | Myotonic Dystrophy Type 2 | Pompe Disease (Late-onset) | Spinal Muscular Atrophy Type 3 | Myotonic Dystrophy Type 1 (DM1) | Facioscapulohumeral Muscular Dystrophy 1 | Inclusion Body Myositis, Sporadic

Germany
Prof. Dr. Benedikt Schoser

Completed

Clinical Outcome Measures in Myotonic Dystrophy Type 2 (COMEDY-2)

Myotonic Dystrophy Type 2

Germany
University of Kansas Medical Center
Pfizer

Terminated

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

HER2-positive Breast Cancer | Breast Cancer Metastatic

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
Erdal AYDIN

Not yet recruiting

Comparison of Motor and Sensory Functions of the Hand in Children With Type 1 Diabetes Mellitus and Their Healthy Peers

Type1 Diabetes Mellitus
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

HER2+ Breast Cancer

China
Alliance Foundation Trials, LLC.
Eli Lilly and Company; Pfizer; Genentech, Inc.; Foundation Medicine

Recruiting

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP)

Endometrial Cancer

United States
Diamyd Medical AB

Recruiting

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes (DIAGNODE-3)

Type 1 Diabetes Mellitus

Czechia, Spain, United States, Hungary, Netherlands, Estonia, Germany, Poland, Sweden
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

Search clinical trials for: DM1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations